Compare ADMA Biologics Inc (ADMA) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Hilton Hotels Corporation Common Stock trades at $333.44 (market cap $77.66B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 36.5× ADMA Biologics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HLT | |
|---|---|---|
Market Cap | $2.13B | $77.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $350.22 |
52-Week Low | $7.60 | $256.75 |
Enterprise Value | $2.20B | $90.15B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Hilton Worldwide (HLT) trades at $341.12, up 0.89% with strong technical momentum as price approaches resistance at $342. The stock shows consistent earnings beats with Q1 2026 EPS of $2.01 exceeding expectations of $1.98, while revenue growth continues from $12.04B in 2025 to projected $12.3B in 2026. Analyst consensus remains bullish with 55% buy ratings and a $342.11 price target closely aligned with current levels.
The outlook remains positive given Hilton's market leadership and sustained travel demand, though elevated debt levels and valuation multiples present risks. With technical indicators showing bullish momentum and strong institutional support, the stock appears positioned for continued growth, though investors should monitor debt management and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
